9月17日，港股通创新药板块延续调整行情，港股通创新药ETF（520880）100%布局创新药研发公司， 盘中一度下探2%，场内最终收跌0.94%日线四连阴，成交3.39亿元。 成份股方面，MIRXES-B、同源康医药-B下挫逾10%居前；大权重龙头涨跌不一，中国生物制药、石药 集团分别下跌2.82%、2.63%，百济神州、翰森制药涨逾1%。 消息面上，近期创新药利好仍多，为多头"越跌越买"提供充足动力。 政策面，国家药监局发布《关于优化创新药临床试验审评审批有关事项的公告》，明确提出对符合要求 的创新药临床试验申请设立"30日审评审批通道"，进一步推动创新药研发提速。 产业方面，开源证券指出，下一代IO、减重、小核酸、Protac、KRAS、TCE、自免双抗等七个创新药 赛道市场空间巨大，目前正在发生着积极变化，或在短期内有望迎来价值拐点。 基本面上，据西南证券统计，今年上半年，港股创新药板块实现归母净利润18亿元，利润首次扭亏为 盈。当前，创新药产业已步入一个以盈利驱动为主的新周期，基本面已明确出现拐点。 【一键配置创新药硬科技，配置认准港股通创新药ETF（520880）】 日前，港股通创新药ETF（52 ...

智通财经APP获悉，香港最新施政报告发布，市场当前静待美联储9月议息会议结果，港股今日高开高 走，恒科指大涨超4%刷新近四年新高。截止收盘，恒生指数涨1.78%或469.88点，报26908.39点，全日 成交额为3602.84亿港元；恒生国企指数涨2.24%，报9596.77点；恒生科技指数涨4.22%，报6334.24点。 银河证券指出，展望后市，建议关注业绩增速较高，但估值整体仍然处于中低水平的可选消费、医疗保 健等板块；政策利好增多或政策利好持续发酵的板块，例如AI产业链、"反内卷"行业、消费行业等；在 海内外不确定性因素的扰动下，分红水平较高的金融板块有望为投资者提供较为稳定的回报。 蓝筹股表现 百度集团-SW(09888)领跑蓝筹。截至收盘，涨15.72%，报131港元，成交额88.97亿港元，贡献恒指 35.75点。招商局集团与百度9月15日签署战略合作协议。据悉，双方将围绕大模型、云计算等前沿人工 智能技术，在科创产业、交通物流、综合金融、地产园区等领域开展合作。值得一提的是，百度自研芯 片昆仑芯此前斩获中国移动10亿级大单，此外，市场对其人工智能和自动驾驶领域也持续看好。 其他蓝筹股方面，海 ...

Core Viewpoint - Daiwa maintains a "Buy" rating for China Biologic Products (01177) and raises the target price from HKD 5.6 to HKD 10, reflecting an upward revision in revenue and earnings forecasts due to improved sales of innovative drugs and expected dividend income from Sinovac Biotech [1] Group 1: Financial Projections - Revenue forecasts for China Biologic Products for 2025 to 2027 have been adjusted upward by 1% to 6% [1] - Earnings per share estimates have been increased by 56% to 106% [1] Group 2: Product Development - The sales of innovative drugs are progressing as expected, with a 27% year-on-year increase in revenue for innovative drug products, reaching RMB 7.8 billion in the first half of the year [1] - The company anticipates launching a total of 21, 26, and over 35 innovative products in 2025, 2026, and 2027, respectively [1] Group 3: New Drug Launches - The report highlights three new drugs expected to be launched by 2027: TQC3721 (PDE3/4), LM-302 (Claudin18.2 ADC), and TQC2731 (TSLP mAb) [1] - The authorization deal for TQC3721 (PDE3/4 inhibitor) is expected to be completed within 2025, as the company is revising terms with potential partners [1]

Market Performance - The A-share market experienced a narrow fluctuation in the morning of September 17, 2023, with a sudden collective rise in the three major indices around 10:30 AM, leading to all indices turning positive. The ChiNext Index rose over 1.5%, reaching a nearly three-year high, while the leading stock, CATL, hit a new high in its adjusted price [1][2] - By midday, the Shanghai Composite Index increased by 0.41%, the Shenzhen Component Index rose by 1.02%, and the ChiNext Index saw a gain of 1.74% [2] Stock Highlights - CATL, a leading stock in the ChiNext Index, surged with its adjusted price reaching a historical high, with an intraday increase approaching 8%. Other notable stocks included Changying Precision, which saw an intraday rise exceeding 16%, along with Sanhua Group, Yilian Network, Xinwangda, and Changchuan Technology, which also performed strongly [4] - In the Hong Kong market, the Hang Seng Index rose significantly, reaching a nearly four-year high, with Baidu Group-SW experiencing an intraday increase of over 12% and a cumulative rise of over 40% since September [9][10] Sector Performance - In terms of sector performance, the top gainers included the electric equipment, automotive, coal, and home appliance sectors, while the social services and agriculture sectors faced declines [7]

宁德时代（300750）引爆行情。 A股市场今天早盘窄幅震荡，10:30左右三大股指突然集体拉升，其中创业板指走势强劲，盘中再度创出近三年多新高。截至中午收盘，上证指数上涨 0.41%，深证成指上涨1.02%，创业板指上涨1.74%。 创业板指成份股中，龙头股宁德时代大涨，盘中复权价再创历史新高，涨幅一度接近8%。长盈精密（300115）大涨，盘中涨幅一度超过16%。此外，三 环集团（300408）、亿联网络（300628）、欣旺达（300207）、长川科技（300604）等多股盘中涨幅也居于市场前列。 行业板块方面，若按照申万一级行业划分，电力设备、汽车、煤炭、家用电器等板块盘中涨幅居前，社会服务、农林牧渔等板块盘中跌幅居前。 *ST东通四个交易日股价"腰斩" A股市场今天（9月17日）早盘窄幅震荡，10:30左右三大股指突然集体拉升，并全部翻红。其中创业板指涨超1.5%，盘中创出近三年多新高，龙头股宁德 时代复权价再创新高。 港股市场今天上午亦整体上行，恒生指数盘中再度刷新近四年新高。 创业板指大涨 "宁王"复权价再创新高 今天上午*ST东通（300379）股价再度跌停，这是该股连续第3个交易日"20cm ...

Core Viewpoint - Daiwa's research report indicates that China National Pharmaceutical Group's innovative drug sales are progressing as expected, with an upward revision of the three-year product launch plan, projecting a total of 21, 26, and over 35 innovative products by 2025, 2026, and 2027 respectively [1] Group 1: Product Launch and Projections - The main change for China National Pharmaceutical Group is the addition of three new drugs in 2027: TQC3721 (PDE3/4), LM-302 (Claudin 18.2 ADC), and TQC2731 (TSLP mAb) [1] - The company anticipates that the licensing deal for TQC3721 (PDE3/4 inhibitor) will be completed within 2025, as it is currently revising terms with potential partners [1] Group 2: Financial Outlook - Daiwa maintains a "Buy" rating for China National Pharmaceutical Group, raising the target price from HKD 5.6 to HKD 10 based on discounted cash flow [1] - Revenue forecasts for the company from 2025 to 2027 have been increased by 1% to 6%, with earnings per share estimates raised by 56% to 106%, reflecting the upward revision in innovative drug sales and other income projections due to expected continued dividend income from Sinovac Biotech [1]

9月17日早盘，港股通创新药板块继续调整。港股通创新药ETF（520880）100%布局创新药研发类公 司，盘中下探2%，现跌逾1%，实时成交超1.8亿元。 值得关注的是，港股通创新药ETF（520880）场内延续宽幅溢价，显示买盘强劲，低吸资金或不在少 数。截至昨日，520880已连续11日吸金，金额合计超6亿元。 成份股方面，大权重龙头股多数下跌，中国生物制药一度下挫逾5%，石药集团、信达生物、康方制 药、三生制药等多股跌逾3%，百济神州逆市翻红。 业绩验证行业高景气，据西南证券统计，港股创新药已进入盈利期。今年上半年，港股创新药板块实现 归母净利润18亿元，利润首次扭亏为盈。当前，创新药产业已步入一个以盈利驱动为主的新周期，基本 面已明确出现拐点。头部企业在商业化产品的推广中实现盈利，海外的授权及全球临床突破也在加速研 发价值的转化。此次产业趋势的变化标志着十年的技术积累正在逐步转化为实际的商业成果。 【国产创新药硬核崛起，配置认准港股通创新药ETF（520880）】 日前，港股通创新药ETF（520880）跟踪的恒生港股通创新药精选指数"提纯"修订生效，完全剔除 CXO，并精选纳入14家创新药研发类公 ...

Group 1 - The Hong Kong innovative drug concept stocks experienced a significant decline on September 17, with major companies like China Biologic Products, Weiya Bio, and Fosun Pharma dropping over 4% [1] - Other companies such as Junshi Biosciences, Rongchang Biopharma, and Innovent Biologics also saw declines exceeding 3% [1]

港股创新药概念股震荡下挫，中国生物制药、维亚生物、复星医药跌超4%，君实生物、荣昌生物、信 达生物多股跌超3%。 ...

Market Overview - The Hang Seng Index slightly declined by 8 points or 0.03%, closing at 438 points on September 16, 2025[1] - The Hang Seng Tech Index rose by 0.6%, closing at 6,077 points[1] - Market turnover was recorded at HKD 294.1 billion, with a net outflow of HKD 3.18 billion from the Hong Kong Stock Connect[1] Economic Indicators - Investor sentiment is cautious, awaiting the outcome of the upcoming FOMC meeting[1] - The U.S. Federal Reserve's potential rate cut is anticipated to have limited impact on Hong Kong stocks due to already high valuations[2] - Sectors sensitive to interest rates, such as AI, robotics, semiconductors, and real estate, may benefit more directly from monetary policy changes[2] Sector Performance - The automotive parts sector saw a significant rise, with Sanhua Intelligent Controls (2050 HK) increasing by 12.8%[3] - The pharmaceutical sector experienced minor declines, with a focus on innovative drugs and leading CXO companies[3] - The renewable energy sector showed mixed performance, with solar stocks generally rising, such as Xinyi Solar (968 HK) up by 2.1%[4] Company Insights - Chaoyun Group (6601 HK) reported a 7.2% increase in revenue to RMB 1.34 billion, with pet category revenue doubling to RMB 96 million, a growth of 101.4%[5][6] - The overall gross margin improved by 2.9 percentage points to 49.3%[5] - The company plans to expand its offline pet store count to 200 by 2027 and is expected to maintain a high dividend payout ratio of 80%[8] Investment Strategy - The report suggests focusing on technology leaders and sectors benefiting from industrial upgrades, such as semiconductors and AI, amidst market volatility[9] - The anticipated rate cut by the Fed is expected to attract foreign capital back to Hong Kong stocks, with a focus on sectors showing strong earnings certainty[9]